<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510497</url>
  </required_header>
  <id_info>
    <org_study_id>Riddler 055794</org_study_id>
    <secondary_id>5U19AI055794</secondary_id>
    <nct_id>NCT00510497</nct_id>
  </id_info>
  <brief_title>Autologous Dendritic Cell Vaccine in HIV1 Infection</brief_title>
  <official_title>Phase I/II Evaluation of Therapeutic Immunization With Autologous Dendritic Cells Pulsed With Autologous, Inactivated HIV-1 Infected, Apoptotic Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharon Riddler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to look at the safety and tolerability of immunization with dendritic cell
      vaccine prepared using the patient's own cells and virus. It also aims to explore the
      virologic efficacy of the vaccine as determined by a decrease in the viral load 12 weeks
      after analytic treatment interruption.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II, open label, single-arm, single-site clinical trial designed to evaluate
      the safety and antiviral activity of the ApB DC vaccine, a therapeutic vaccine derived from
      autologous dendritic cells loaded with autologous HIV-1 infected apoptotic cells. The study
      will be conducted in three phases. The first is the pre-vaccination phase that includes study
      entry, isolation of autologous virus, and initiation of antiretroviral therapy. Once the
      patient's viral load has been suppressed to undetectable levels (&lt;50 copies/mL) and
      sufficient virus has been isolated, the second phase will begin. This includes leukapheresis
      in order to harvest monocytes and lymphocytes necessary for vaccine preparation. Three
      vaccine doses will be administered subcutaneously every other week. Six weeks after the last
      vaccination, the third phase, analytic treatment interruption (ATI) phase, will begin. A
      fourth, booster dose of vaccine will be given two weeks after the start of treatment
      interruption. The treatment interruption will be continued for twelve weeks after which the
      primary HIV provider will decide whether or not antiretroviral therapy should be restarted.
      CD4 and viral load will be closely monitored throughout the study especially during treatment
      interruption. Follow-up will be continued for 24 weeks after the 12-week treatment
      interruption.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine.</measure>
    <time_frame>80 weeks</time_frame>
    <description>AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART)</measure>
    <time_frame>at the end of 12 weeks treatment interruption</time_frame>
    <description>Log10 Change in HIV RNA set point comparing pre-ART to 12 weeks after treatment interruption</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Autologous HIV-1 ApB DC Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who will receive ApB Dendritic cell vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous HIV-1 ApB DC Vaccine</intervention_name>
    <description>Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
    <arm_group_label>Autologous HIV-1 ApB DC Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV-1 infection.

          -  CD4 greater than or equal to 350 cells/mL within 8 weeks prior to study entry.

          -  Plasma HIV-1 RNA level of 5000-100,000 copies/mL within 8 weeks prior to study entry.

          -  Antiretroviral therapy naive.

          -  Willingness to interrupt ART for at least 12 weeks.

          -  Written informed consent.

        Exclusion Criteria:

          -  Treatment within 30 days prior to study entry with systemic steroids or other
             immunosuppressives, or any underlying disease which may require use of such
             medications during the study period.

          -  Receipt of any vaccinations other than routine ones within 6 months of study entry

          -  Pregnancy or breastfeeding

          -  Previous or current CDC Category C event

          -  Receipt of any investigational product within 12 weeks prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon A Riddler, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Macatangay BJ, Riddler SA, Wheeler ND, Spindler J, Lawani M, Hong F, Buffo MJ, Whiteside TL, Kearney MF, Mellors JW, Rinaldo CR. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J Infect Dis. 2016 May 1;213(9):1400-9. doi: 10.1093/infdis/jiv582. Epub 2015 Dec 8.</citation>
    <PMID>26647281</PMID>
  </results_reference>
  <results_reference>
    <citation>Whiteside TL, Piazza P, Reiter A, Stanson J, Connolly NC, Rinaldo CR Jr, Riddler SA. Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection. Clin Vaccine Immunol. 2009 Feb;16(2):233-40. doi: 10.1128/CVI.00066-08. Epub 2008 Nov 26.</citation>
    <PMID>19038780</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2007</study_first_submitted>
  <study_first_submitted_qc>August 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2007</study_first_posted>
  <results_first_submitted>January 12, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2016</results_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Sharon Riddler</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>dendritic cell</keyword>
  <keyword>therapeutic vaccine</keyword>
  <keyword>HIV-1</keyword>
  <keyword>apoptotic cells</keyword>
  <keyword>Phase I/II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous HIV-1 ApB DC Vaccine</title>
          <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>11 particpants were enrolled but one received no study vaccines and was withdrawn and not included in any analyses.</population>
      <group_list>
        <group group_id="B1">
          <title>Autologous HIV-1 ApB DC Vaccine</title>
          <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.9" lower_limit="20" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine.</title>
        <description>AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004</description>
        <time_frame>80 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous HIV-1 ApB DC Vaccine</title>
            <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Autologous HIV-1 ApB DC Vaccine.</title>
          <description>AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004</description>
          <units>participants with Grade 3 events related</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART)</title>
        <description>Log10 Change in HIV RNA set point comparing pre-ART to 12 weeks after treatment interruption</description>
        <time_frame>at the end of 12 weeks treatment interruption</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous HIV-1 ApB DC Vaccine</title>
            <description>Subjects who will receive ApB Dendritic cell vaccine
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
          </group>
        </group_list>
        <measure>
          <title>Virologic Efficacy (HIV-1 Viral Load at End of ATI Minus Viral Load Prior to ART)</title>
          <description>Log10 Change in HIV RNA set point comparing pre-ART to 12 weeks after treatment interruption</description>
          <units>log10 HIV RNA</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" lower_limit="-0.60" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Autologous HIV-1 ApB DC Vaccine</title>
          <description>Subjects who will receive ApB Dendritic cell vaccine (does not include one enrolled participant who received no study treatment)
Autologous HIV-1 ApB DC Vaccine: Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>grade 3 severe pruritus and injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon A. Riddler, MD, MPH</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>412-383-1675</phone>
      <email>riddler@pitt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

